The Annual General Meeting of Eckert & Ziegler SE (ISIN DE0005659700) today approved the proposal of the Executive Board and Supervisory Board and resolved to pay a dividend of EUR 0.22 per share (previous year: EUR 0.17) for the 2025 fiscal year. This increase of nearly 30% underscores the company's robust financial health and commitment to returning value to shareholders.
As in previous years, the Annual General Meeting was held as an in-person event, right next to the Eckert & Ziegler SE headquarters in Berlin. In total, 55.37% of the company’s share capital was represented. The Annual General Meeting endorsed the members of the Executive Board and the Supervisory Board of Eckert & Ziegler SE for the 2025 fiscal year and approved all items on the agenda by a large majority.
The approval of a higher dividend signals confidence in the company's ongoing growth and profitability. Eckert & Ziegler is a leading specialist for isotope-related components in nuclear medicine and radiation therapy, serving a critical role in healthcare. The dividend increase may attract income-focused investors and strengthen the company's market position.
The detailed voting results of the Annual General Meeting and the CEO’s presentation are available on the Eckert & Ziegler SE website: https://www.ezag.com/investors/annual-general-meeting/.
Eckert & Ziegler SE, with more than 1,000 employees, offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. The company's shares are listed in the TecDAX index of Deutsche Börse. This dividend announcement is a key indicator of the company's stability and future prospects in the growing field of nuclear medicine.
